Subject(s)
Facial Dermatoses/diagnosis , Hypopigmentation/diagnosis , Neck , Neoplasms, Adnexal and Skin Appendage/diagnosis , Neoplasms, Adnexal and Skin Appendage/pathology , Skin Neoplasms/diagnosis , Adult , Biopsy , Diagnosis, Differential , Facial Dermatoses/pathology , Humans , Hypopigmentation/pathology , Male , Skin/pathology , Skin Neoplasms/pathologySubject(s)
Angiogenesis Inhibitors/adverse effects , Cicatrix/pathology , Colorectal Neoplasms/drug therapy , Recombinant Fusion Proteins/adverse effects , Skin Ulcer/chemically induced , Vascular Endothelial Growth Factor A/antagonists & inhibitors , Abdomen , Angiogenesis Inhibitors/therapeutic use , Bandages , Colorectal Neoplasms/surgery , Humans , Male , Middle Aged , Necrosis/chemically induced , Receptors, Vascular Endothelial Growth Factor/therapeutic use , Recombinant Fusion Proteins/therapeutic use , Recurrence , Remission, Spontaneous , Skin Ulcer/pathology , Skin Ulcer/therapy , Withholding TreatmentABSTRACT
BACKGROUND: Treatment of oral erosive lichen planus is considered a therapeutic challenge. Various systemic and topical agents aimed at controlling the symptoms, rather than curing the lesions, have been used with varying results. OBJECTIVE: To evaluate the response to treatment with antimalarial drugs in patients with oral erosive lichen planus. METHODS: Eight patients diagnosed with oral erosive lichen planus were treated with antimalarial agents. The first clinical evaluation was made after a month of treatment and then every 2-3 months. Baseline ophthalmologic examinations were performed, and laboratory values were monitored before and during treatment. RESULTS: All studied patients who had previously been resistant to other treatments responded favorably. Pain relief and reduced erythema and erosions were observed after of a mean of 2.4 months. CONCLUSION: Antimalarials may be useful for the treatment of oral erosive lichen planus. They are easily administered and affordable, with few adverse effects.
Subject(s)
Antimalarials/therapeutic use , Lichen Planus, Oral/drug therapy , Aged , Aged, 80 and over , Female , Humans , Male , Middle Aged , Retrospective Studies , Treatment OutcomeABSTRACT
Locoregional cutaneous metastases of melanoma (LCMM) represent a therapeutic challenge. Many treatment options are available with varying results. The combination of cryotherapy and imiquimod, two treatments with a possible synergistic effect, has not yet been described for treating this disease. In this paper, we aimed to show the response of LCMM to cryotherapy combined with topical imiquimod 5%. A retrospective review of 20 patients diagnosed with LCMM and treated with cryotherapy combined with topical imiquimod 5% between November 2000 and May 2014 at three institutions was performed. The locoregional cutaneous response was evaluated. After a mean of five sessions, 13 patients (65%) responded to treatment, eight (40%) of these completely and five (25%) partially. Systemic disease progressed in 16 (80%) patients. Cryotherapy followed by topical imiquimod 5% is simple to apply, has minimal adverse effects and provides response rates similar to other, more complex treatment options.